MedTrace Logo

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04990037 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-06-29

No results posted yet for this study

Summary

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.

Conditions

Interventions

DRUG

CAN04

Administered intravenously

DRUG

FOLFIRINOX

Administered intravenously

Sponsors & Collaborators

  • Cantargia AB

    lead INDUSTRY

Principal Investigators

  • Ignacio Garcia-Ribas, MD, PhD · Cantargia AB

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2023-05-30
Completion
2023-06-15
FDA Drug
Yes

Countries

  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04990037 on ClinicalTrials.gov